March 2024 - World School of Life Sciences IP

Will Merck pay royalty charges to John Hopkins University over Keytruda® patents?

Tanu Goyal March 22, 2024

Pembrolizumab, a monoclonal antibody marketed under the brand name Keytruda®, was Merck & Co’s highest-grossing product in FY 2023 with sales of about 25 billion

Biocon Biologics’ Yesafili® Gets Market Entry Date in Canada

Tanu Goyal March 8, 2024

Following up on our previous post on looming biosimilar approvals over Eylea®(Aflibercept), on March 4, Biocon Biologics Limited (BBL), a subsidiary of Biocon Limited, announced

Cell and Gene Therapy: The need of the hour

Tanu Goyal March 3, 2024

For many years, conventional medical approaches involving medication and surgery have significantly enhanced individuals’ well-being. However, certain diseases persist without a definitive cure, and these

WSLI

Welcome to World School of Life Sciences IP, a pioneer in empowering minds to dominate the ever-evolving landscape of patents and pharmaceutical innovations.